# Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

> **NCT06444178** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 224 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Aspirin
- **DRUG:** REGN9933
- **DRUG:** REGN7508
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT06444178
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-30
- **Primary completion:** 2025-04-07
- **Final completion:** 2025-07-09
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06444178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06444178, "Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06444178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*